Physician profile
Ivan Law
NPI 1720260441
$5,469.16
in general payments reported to CMS, 2019-2025
41 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $72.96 · 2021: $35.99 · 2022: $483 · 2023: $1,273 · 2024: $1,307 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Education: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.33 |
| Education | $896.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $707.30 | 2019-2025 | Lynparza, Imfinzi |
| Sobi, INC | $400.74 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $364.47 | 2022-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $330.15 | 2019-2025 | |
| Celgene Corporation | $305.33 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $274.23 | 2020-2025 | Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $240.19 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $225.35 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $217.35 | 2024-2025 | |
| Astellas Pharma US INC | $196.90 | 2022-2025 | Vyloy, Xospata, Xtandi |
| Incyte Corporation | $192.81 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $189.80 | 2023-2025 | Ojjaara, Zejula, Shingrix |
| Novartis Pharmaceuticals Corporation | $183.38 | 2021-2025 | |
| Daiichi Sankyo INC. | $177.64 | 2022-2025 | Enhertu, Datroway |
| Lifenet Health | $157.39 | 2025 | Theragenesis Wound Matrix |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $118.22 | 2019-2023 | Lumakras |
| Janssen Biotech, INC. | $117.70 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Beigene USA, INC. | $115.04 | 2022-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $104.97 | 2023-2025 | Xpovio |
| Genzyme Corporation | $85.24 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Novocure INC. | $77.34 | 2022-2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $72.64 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $66.82 | 2023-2024 | Pylarify |
| Eisai INC. | $58.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.34 | 2021-2025 | |
| Abbvie INC. | $41.51 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $36.94 | 2023 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $36.27 | 2020-2023 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $34.77 | 2025 | Tivdak |
| Agios Pharmaceuticals, INC. | $32.14 | 2022-2024 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $31.41 | 2023 | Onivyde, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $18.54 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.55 | 2024 | Hyqvia |
| Tactile Systems Technology INC | $16.68 | 2025 | Nimbl, Flexitouch Plus |
| Puma Biotechnology, INC. | $16.43 | 2024 | |
| Morphosys, US INC. | $16.19 | 2022 | |
| Immunocore Limited | $15.58 | 2025 | Kimmtrak |
| Accord Healthcare, INC. | $14.80 | 2024 | |
| Digestive Care, INC. | $14.06 | 2023 | Pertzye |
| Coherus Oncology, INC. | $14.00 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.